Atlantic Sapphire reported an 87% revenue increase in 2025, rising from $23 million to over $43 million due to higher production volume and premium pricing. Operational improvements were seen across key performance indicators, including stable biology and increased production parameters. However, the company faces financial challenges in 2026, prompting a $10 million bridge loan to sustain operations until reaching EBITDA breakeven. Efforts continue to improve feed conversion efficiency, a critical operational metric linked to ongoing biofiltration and degassing projects.
Regentis Biomaterials shares surged over 500% intraday before falling 9.15% in after-hours trading following the company's announcement that it withdrew its Registration Statement for a public offering. The regenerative medicine firm decided not to p...
Elon Musk's SpaceX recently went public, raising questions about a potential IPO for its Starlink subsidiary. Data from prediction market Kalshi shows only a 7-10% chance of a Starlink IPO announcement before mid-2027. Meanwhile, Musk predicts SpaceX...
Goodfirms has published its 2026 rankings of top technology service providers across six categories: mobile app, software, web development, digital marketing, SEO, and AI development. These rankings are based on over 1.2 million verified client revie...
Alvotech announced a $152 million public offering and concurrent private placement of ordinary shares priced at $3.75 each. The public offering includes 22.7 million shares, with an option for underwriters to buy an additional 3.4 million shares. The...
Alvotech announced pricing and allocation of a $152 million public share offering in the US and a concurrent private placement in Europe at $3.75 per share. The company expects total proceeds up to $165 million if underwriters exercise their full opt...
